Marksans Pharma Limited announced that its wholly owned UK subsidiary, Relonchem Limited, has received Marketing Authorization from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for its Exemestane 25mg film-coated tablets.
In the exchange filings, the company shared, “Marksans Pharma Limited (Reuters: MARK.BO; Bloomberg: MRKS IN; NSE: MARKSANS; BSE: 524404) hereby announces that its wholly owned subsidiary Relonchem Limited in UK has received Marketing Authorization for its product Exemestane 25mg film-coated tablets from UK MHRA.”
This approval marks another milestone for Marksans Pharma as it strengthens its position in the UK and European pharmaceutical markets. The newly authorized Exemestane tablets are used primarily in the treatment of breast cancer in postmenopausal women, especially those with estrogen receptor-positive tumors.
With this authorization, Relonchem Limited will be able to market and distribute Exemestane 25mg tablets across the UK, expanding Marksans Pharma’s oncology portfolio and reinforcing its focus on high-growth therapeutic segments.
